Empowering Oncology Decisions
DiagnoCure is a life sciences company that develops and commercializes high-value cancer diagnostic tests that increase clinician and patient confidence in making critical treatment decisions.
Special Announcement
New collaboration with Signal Genetics
News
- January 26, 2012 - DiagnoCure announces publication of a meta-analysis on Previstage GCC Colorectal Cancer Test
- January 16, 2012 - DiagnoCure announces Fourth Quarter 2011 and Year-End Results
Events
|
0.72
+0.01
|
Open: 0.71 $CAN.
Quotes are delayed.
|
Investors
- Fact Sheet (PDF)
- Business strategy
- Financial information
- 2010 Annual Report
